Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

Similar articles for PubMed (Select 16904298)

1.

Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.

Skapinakis P, Papatheodorou T, Mavreas V.

Eur Neuropsychopharmacol. 2007 Jan 15;17(2):79-93. Epub 2006 Aug 10. Review.

PMID:
16904298
2.

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.

Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF.

Mol Psychiatry. 2006 Jul;11(7):622-32. Epub 2006 Apr 4. Review. Erratum in: Mol Psychiatry. 2006 Aug;11(8):795.

PMID:
16585942
3.

Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.

Dold M, Aigner M, Lanzenberger R, Kasper S.

Int J Neuropsychopharmacol. 2013 Apr;16(3):557-74. doi: 10.1017/S1461145712000740. Epub 2012 Aug 29. Review.

PMID:
22932229
4.

Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study.

Fineberg NA, Sivakumaran T, Roberts A, Gale T.

Int Clin Psychopharmacol. 2005 Jul;20(4):223-6.

PMID:
15933483
5.

[Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials].

Dold M, Aigner M, Lanzenberger R, Kasper S.

Fortschr Neurol Psychiatr. 2011 Aug;79(8):453-66. doi: 10.1055/s-0031-1273397. Epub 2011 Aug 1. Review. German.

PMID:
21809258
6.

Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials.

Fineberg NA, Stein DJ, Premkumar P, Carey P, Sivakumaran T, Vythilingum B, Seedat S, Westenberg H, Denys D.

Int Clin Psychopharmacol. 2006 Nov;21(6):337-43.

PMID:
17012980
7.

Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.

Hollander E, Baldini Rossi N, Sood E, Pallanti S.

Int J Neuropsychopharmacol. 2003 Dec;6(4):397-401.

PMID:
14604454
8.

Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.

Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L.

Eur Neuropsychopharmacol. 2005 Jan;15(1):69-74.

PMID:
15572275
9.

Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review.

Sareen J, Kirshner A, Lander M, Kjernisted KD, Eleff MK, Reiss JP.

J Affect Disord. 2004 Oct 15;82(2):167-74. Review.

PMID:
15488245
10.
11.
12.

Antipsychotic treatment in obsessive-compulsive disorder: a literature review.

Keuneman RJ, Pokos V, Weerasundera R, Castle DJ.

Aust N Z J Psychiatry. 2005 May;39(5):336-43. Review.

PMID:
15860020
13.

Use of atypical antipsychotics in refractory depression and anxiety.

Nemeroff CB.

J Clin Psychiatry. 2005;66 Suppl 8:13-21. Review.

PMID:
16336032
14.

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.

Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F.

J Clin Psychopharmacol. 2008 Oct;28(5):550-4. doi: 10.1097/JCP.0b013e318185e735.

PMID:
18794652
15.

Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.

Dold M, Aigner M, Lanzenberger R, Kasper S.

Int J Neuropsychopharmacol. 2015 May 4. pii: pyv047. doi: 10.1093/ijnp/pyv047. [Epub ahead of print]

16.

8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.

Maina G, Pessina E, Albert U, Bogetto F.

Eur Neuropsychopharmacol. 2008 May;18(5):364-72. doi: 10.1016/j.euroneuro.2008.01.001. Epub 2008 Feb 15.

PMID:
18280710
17.

Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.

van Nimwegen L, de Haan L, van Beveren N, Laan W, van den Brink W, Linszen D.

J Clin Psychopharmacol. 2008 Apr;28(2):214-8. doi: 10.1097/JCP.0b013e318166f520.

PMID:
18344733
19.

[Combination of risperidone and serotonergic antidepressants in refractory obsessive-compulsive disorder].

Salmerón JM, Alcántara AG, Barcia D.

Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1998 Nov-Dec;26(6):399-402. Spanish.

PMID:
9972593
20.

A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.

Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ.

J Clin Psychiatry. 2009 Jun;70(6):863-8. doi: 10.4088/JCP.08m04369. Epub 2009 May 5.

PMID:
19422759
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk